

Colonoscopy Education Day Top Colonoscopy articles 2017

October 25, 2017

Dr. Carla Nash

Disclosures

Relationships with commercial interest

- Honoraria: Abbvie

Honoraria: Phizer

- Managing potential bias:
 - No expected bias in this presentation



Outline

- Patient preparation
- Technique
- Devices



Patient preparation

- 18-30% colonoscopies hampered by poor bowel prep
- Adequacy of bowel prep multifactorial
 - Dietary restriction
 - Split dose/same day purgative
 - Comorbidities (DM, constipation)
 - Compliance
- Risk factors for poor bowel prep
 - Non compliance with instructions
 - Longer wait times
 - Lower education level

Chan, BMC Gastroenterol, 2011



Xiaoyang Guo, MD,^{1,*} Zhiping Yang, MD,^{1,*} Lina Zhao, MD,^{2,*} Felix Leung, MD,^{3,4} Hui Luo, MD,¹ Xiaoyu Kang, MD,¹ Xin Li, MD,⁵ Hui Jia, MD,¹ Shengye Yang, MD,¹ Qin Tao, MD,¹ Yanglin Pan, MD,¹ Xuegang Guo, MD¹

Guo, GIE, 2017

Xian, China; North Hills, Los Angeles, California, USA

- English studies with terms educate/instruct AND colonoscopy or bowel preparation
- RCT's comparing enhanced instructions (EI) vs regular instructions (RI)
- Study participants: >18 years old undergoing colonoscopy
- Outcome: Rate of adequate bowel prep
 - Boston BP score >/=5
 - Ottawa BP score <6
 - Universal Prep assessment scale <3
 - Harefield Cleansing scale A or B



Xiaoyang Guo, MD, ^{1,*} Zhiping Yang, MD, ^{1,*} Lina Zhao, MD, ^{2,*} Felix Leung, MD, ^{3,4} Hui Luo, MD, ¹ Xiaoyu Kang, MD, ¹ Xin Li, MD, ⁵ Hui Jia, MD, ¹ Shengye Yang, MD, ¹ Qin Tao, MD, ¹ Yanglin Pan, MD, ¹ Xuegang Guo, MD

Xian, China; North Hills, Los Angeles, California, USA




Figure 1. Search strategies. *RCT*, randomized controlled trial.



Xiaoyang Guo, MD, ^{1,*} Zhiping Yang, MD, ^{1,*} Lina Zhao, MD, ^{2,*} Felix Leung, MD, ^{3,4} Hui Luo, MD, ¹ Xiaoyu Kang, MD, ¹ Xin Li, MD, ⁵ Hui Jia, MD, ¹ Shengye Yang, MD, ¹ Qin Tao, MD, ¹ Yanglin Pan, MD, ¹ Xuegang Guo, MD

Xian, China; North Hills, Los Angeles, California, USA

TABLE 1. Details of studies included in this meta-analysis

	Calderwood et al, 2011 ¹⁸	Kang et al, 2015 ⁵	Lee et al, 2015 ¹⁵	Liu et al, 2014 ¹²
Location	USA	China	Korea	China
Design	RCT	RCT	RCT	RCT
Blinding	Single	Single	Single	Single
Total number	969	770	386	605
El	Visual aid	Social media app	Telephone, SMS	Telephone
RI	Written instructions	Verbal and written instructions	Verbal and written instructions	Verbal and written instructions
Indications	Screening	Mixed	Screening	Mixed
Primary endpoint	Rate of adequate BP	Rate of adequate BP	Rate of adequate BP	Rate of adequate BP
BP scale	BBPS	OBPS	BBPS	OBPS
Purgative	4 L of PEG or 4 L of PEG + bisacodyl	4 L of PEG-ELP	2 L of PEG $+$ ascorbate solution	2 L of PEG-ELP or 1.5 L of sodium phosphate
Administration method	NR	Split dose	Split dose	Single dose
Diet restriction	NR	Clear liquid	Low-residue	Clear liquid
Timing of El	NR	15 days before	2 days before	1 day before
Cecum intubation rate	NR	97.2% vs 93.2%	99.2% vs 98.5%	94.9% vs 85.4%
Insertion time (min), mean \pm SD	7.0 \pm 3.7 vs 7.0 \pm 3.7	7.2 \pm 4.6 vs 9.1 \pm 4.8	3.5 \pm 3.5 vs 3.4 \pm 3.1	7.7 \pm 5.1 vs 7.6 \pm 4.3
Withdrawal time (min), mean \pm SD	8.0 \pm 3.7 vs 7.0 \pm 3.0	7.2 \pm 2.2 vs 7.4 \pm 2.1	9.8 \pm 10.9 vs 9.1 \pm 7.6	6.2 \pm 2.3 vs 7.8 \pm 2.8
BP score, mean \pm SD	6.0 \pm 0.7 vs 6.0 \pm 0.7	3.6 \pm 1.7 vs 4.5 \pm 1.8	6.8 \pm 1.3 vs 6.3 \pm 1.4	3.0 \pm 2.3 vs 4.9 \pm 3.2

RCT, Randomized controlled trial; EI, enhanced instructions; SMS, short message service; RI, regular instructions; BP, bowel preparation; BBPS, Boston Bowel Preparation Scale; OBPS, Ottawa Bowel Preparation Scale; HCS, Harefield Cleansing Scale; UPAS, Universal Preparation Assessment Scale; PEG, polyethylene glycol; NR, not reported; SD, standard deviation.

CARE + RESEARCH

Xiaoyang Guo, MD,^{1,*} Zhiping Yang, MD,^{1,*} Lina Zhao, MD,^{2,*} Felix Leung, MD,^{3,4} Hui Luo, MD,¹ Xiaoyu Kang, MD,¹ Xin Li, MD,⁵ Hui Jia, MD,¹ Shengye Yang, MD,¹ Qin Tao, MD,¹ Yanglin Pan, MD,¹ Xuegang Guo, MD¹

Xian, China; North Hills, Los Angeles, California, USA

	EI		RI			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Random, 95% CI	M–H, Random, 95% CI
Calderwood, 2011	432	477	438	492	17.2%	1.18 [0.78, 1.80]	+
Kang, 2015	318	353	266	352	17.0%	2.94 [1.92, 4.49]	-
Lee, 2015	243	251	118	135	9.6%	4.38 [1.84, 10.43]	
Liu, 2014	249	305	211	300	17.9%	1.88 [1.28, 2.75]	*
Lorenzo, 2015	108	108	146	152	1.4%	9.63 [0.54, 172.74]	+
Modi, 2009	58	84	46	80	13.0%	1.65 [0.87, 3.13]	 • -
Spiegel, 2011	100	132	62	134	15.1%	3.63 [2.15, 6.12]	-
Tae, 2012	95	102	80	98	8.9%	3.05 [1.21, 7.68]	
Total (95% CI)		1812		1743	100.0%	2.35 [1.65, 3.35]	•
Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2				= .008);	$I^2 = 63\%$		0.01 0.1 1 10 100 Favors [RI] Favors [EI]

Figure 2. Forest plot comparing the bowel preparation quality between the enhanced instruction (EI) and regular instruction (RI) groups. *CI*, confidence interval.



Secondary outcomes

Parameter	EI	RI	OR	р
Cecal intubation	97.0%	92.4%	2.77 (1.73-4.42)	<0.001
Insertion time	7.3 +/- 5.3 m	7.9 +/- 6.8 m	MD -0.57 m (- 1.38-0.24)	0.170
Withdrawal time	7.6 +/- 5.3 m	8.5 +/- 4.7 m	MD -0.28 m (- 0.49—0.06)	0.010
PDR	30.8%	36.0%	1.25 (0.93-1.68)	0.140
AE	30.9%	31.7%	0.76 (0.54-1.07)	0.120
Willing to repeat	90.5%	83.1%	1.91 (1.20-3.04)	0.006



Xiaoyang Guo, MD,^{1,*} Zhiping Yang, MD,^{1,*} Lina Zhao, MD,^{2,*} Felix Leung, MD,^{3,4} Hui Luo, MD,¹ Xiaoyu Kang, MD,¹ Xin Li, MD,⁵ Hui Jia, MD,¹ Shengye Yang, MD,¹ Qin Tao, MD,¹ Yanglin Pan, MD,¹ Xuegang Guo, MD¹

Xian, China; North Hills, Los Angeles, California, USA

- Enhanced instructions in addition to written/verbal instructions can improve bowel prep quality
 - Compliance is improved
 - ?more understandable instructions, more interactive, more repetition improves memory
- El results in improved procedure factors
 - Higher cecal intubation rates, shorter insertion times



<u>Technique</u>

Interval cancers after colonoscopy are more common in right colon
 Brenner, Ann Intern Med, 2011
 Singh, Gastro, 2010

- Proximal adenomas associated with higher risk of subsequent advanced neoplasia

 Martinez, Gastro, 2009
- May be due to missed right sided lesions or different polyp pathology
 - Colonoscopy techniques such as tandom colonoscopy, cecal retroflexion, water aided can increase ADR
 - Devices such as 3rd eye retroscope, full spectrum endoscopy



Chuan-Guo Guo¹, Feifei Zhang², Rui Ji¹, Yueyue Li¹, Lixiang Li¹, Xiu-Li Zuo¹, Yan-Qing Li¹


Institutions

- 1 Department of Gastroenterology, Laboratory of Translational Gastroenterology, Shandong University, Qilu Hospital, Jinan, Shandong Province, China
- 2 Department of Epidemiology, School of Public Health, Shandong University, Jinan, Shandong Province, China



- Prospective single blinded study of patients 18-80 years undergoing colonoscopy with intermediate or high risk of advanced adenoma at Shandong University Hospital
- Exclusions: advanced colon cancer, IBD, prior proximal resection, IBD, polyposis syndrome, poor bowel prep, unable to intubate cecum
- Primary outcome: proximal ADR
- Secondary outcomes: PDR, ADR, mean number polyps/adenomas, withdrawal times





➤ Table 1 Baseline characteristics.			
	Segmental re-examination, n=178	Extended withdrawal time, n=182	P value
Age, mean ± SD, years	55.0 ± 11.0	54.9±10.3	0.92
Female sex, n (%)	83 (46.6)	80 (44)	0.61
Colon cancer in first-degree relative, n (%)	9 (5.1)	7 (3.8)	0.58
Smoking, n (%)	46 (25.8)	37 (20.3)	0.21
Previous colonoscopy, n (%)	34 (19.1)	46 (25.3)	0.16
Abdominal surgery, n (%)	16 (9.0)	14 (7.7)	0.66
Quality of bowel preparation, BBPS, n			0.63
• 6	40	35	
• 7	46	48	
• 8	44	55	
• 9	48	44	
BBPS, Boston Bowel Preparation Scale score.			



► Table 2 Detection rates.			
	Segmental re-examination, % (95%CI)	Extended withdrawal time, % (95%CI)	P value
PDR	50.6 (43.2 – 57.9)	55.5 (48.3 – 62.7)	0.13
ADR	38.2 (31.1 – 45.3)	38.5 (31.4 – 45.5)	0.96
 Advanced ADR 	5.6 (3.1 – 10.0)	3.3 (1.5 – 7.0)	0.29
Proximal PDR	41.6 (34.6 – 45.3)	33.5 (26.7 – 48.8)	0.11
Proximal ADR	33.1 (26.2 – 40.1)	23.6 (17.5 – 29.8)	0.045
 Proximal advanced ADR 	2.2 (0.9 – 5.6)	0.5 (0.1 – 3.0)	0.17
CI, confidence interval; PDR, polyp	detection rate; ADR, adenoma detection rate.		



 Segmental re-examination of the proximal colon could increase ADR without extending withdrawal time



Devices

- Cap assisted colonoscopy uses a transparent cap attached to the tip of the colonoscope to flatten folds
- Compared to standard colonoscopy, increases colonic neoplasia detection rate and cecal intubation rate Westwood, Dis Colon Rectum, 2012

Ng, Am J Gastroenterol, 2012



Desai, GIE, 2017)

- Literature review
- Eligible studies:
 - RCT or retrospective with control groups
 - ADR primary outcome
 - Info on proximal adenomas or regional classification
 - Info on individuals with proximal adenomas



TABLE 1. Number of right-sided adenomas reported among CC and SC groups among inclusion studies

TABLE 1. Continued

						Mean	age (y)
Study	Design	Country	Population	Total no. of patients (CC:SC)	Male:female	СС	SC
Rastogi et al 2012 ¹¹	RCT	USA	Screening or surveillance	420 (210:210)	398:22	60.7	61.3
Kim et al 2015 ¹³	Retrospective	South Korea	Screening	1023 (515:508)	549:474	55.0	54.44
Horiuchi et al 2013 ¹²	Retrospective	Japan	Screening, hematochezia, heme-positive stools, other	2301 (1165:1136)	1484:817	65.4	64.8
de Wijkerslooth et al 2012 ¹⁰	RCT	Netherlands	Screening	1339 (656:683)	685:654	60	60
Hewett et al 2010 ²⁸	Tandem study, intervention trial	USA	Screening, surveillance, other	100 (52:48)	57:43	61	62.9
Pohl et al 2015 ²⁹	RCT	USA	Screening, surveillance, heme-positive stools, other	1143 (561:552)	709:404	62	61.5

CC, Cap-assisted colonoscopy; SC, standard colonoscopy; RCT, randomized controlled trial; ADR, adenoma detection rate; NA, not available.



	Right-sided	I ADR n (%)	Right-sided	adenomas n	Right-sided ade	noma per person
Study	СС	sc	СС	sc	СС	SC
Rastogi et al 2012 ¹¹	117 (56%)	90 (43%)	278	169	1.32	.8
Kim et al 2015 ¹³	139 (27%)	86 (16.9%)	236	129	.45	.25
Horiuchi et al 2013 ¹²	221 (19%)	136 (12%)	358	261	.31	.23
de Wijkerslooth et al	104 (16%)	115 (17%)	164	171	.25	.25
Hewett et al 2010 ²⁸	NA	NA	71	88	1.37	1.83
Pohl et al 2015 ²⁹	NA	NA	321	309	.57	.56



Study or Subgroup	Conti Events		Interve Events		Weight	Odds Ratio M-H, Random, 95% C	1		Ratio dom, 95% CI	
de Wijkerslooth 2012	104	656	115	683	25.5%	0.93 [0.70-1.24]		-	-	
Horiuchi 2013	221	1165	136	1136	27.6%	1.72 [1.37-2.17]			-	
Kim DJ 2015	139	515	86	518	25.0%	1.86 [1.37-2.51]			-	
Rastogi 2012	117	210	90	210	21.9%	1.68 [1.14-2.47]			-	
Total (95% CI)		2546		2547	100.0%	1.49 [1.08-2.05]			*	
Total events	581		427							
Heterogeneity. Tau ² = 0				P = .003	3); $I^2 = 799$	%	0.01	0.1	10	100
Test for overall effect: Z	Z = 2.45 (I	P = .01)				0.01	Favors [SC]	Favors [CC]	700

Figure 2. Forest plot of right-sided adenoma detection rate using cap-assisted colonoscopy versus standard colonoscopy. CI, Confidence interval.



 CC leads to 6% more r-ADR compared to SC, 4% more flat adenomas and 3% more diminutive adenomas



Full spectrum colonoscopy

Full-spectrum (FUSE) versus standard forwardviewing colonoscopy in an organised colorectal cancer screening programme

Cesare Hassan, ¹ Carlo Senore, ² Franco Radaelli, ³ Giovanni De Pretis, ⁴ Romano Sassatelli, ⁵ Arrigo Arrigoni, ⁶ Gianpiero Manes, ⁷ Arnaldo Amato, ³ Andrea Anderloni, ⁸ Franco Armelao, ⁴ Alessandra Mondardini, ⁶ Cristiano Spada, ⁹ Barbara Omazzi, ⁷ Maurizio Cavina, ⁵ Gianni Miori, ⁴ Chiara Campanale, ⁹ Giuliana Sereni, ⁵ Nereo Segnan, ² Alessandro Repici^{8,10}

Gut (66):1949-1955

- 658 patients in a FIT based regional CRC screening program randomized to FUSE or SC
- No difference in ADR, A-ADR, SSPDR or per polyp analysis



Endocuff assisted colonoscopy

Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial

SC van Doorn,¹ M van der Vlugt,¹ ACTM Depla,² CA Wientjes,³ RC Mallant-Hent,⁴ PD Siersema,⁵ KMAJ Tytgat, H Tuynman,^{1,2} SD Kuiken,³ GMP Houben,² PCF Stokkers,³ LMG Moons,⁵ PMM Bossuyt,⁶ P Fockens,¹ MW Mundt,⁴ E Dekker¹

Gut 66:438-445

- RCCT 530 patients with endocuff assisted colonoscopy vs 533 standard colonoscopy
- More adenomas in EAC group (722 vs 621) but mean adenomas per patient (1.36 vs 1.17 was not statistically significant (p=0.08) and ADR was similar




Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis

Douglas A. Corley, MD, PhD; Christopher D. Jensen, PhD, MPH; Virginia P. Quinn, PhD, MPH; Chyke A. Doubeni, MD, MPH; Ann G. Zauber, PhD; Jeffrey K. Lee, MD, MAS; Joanne E. Schottinger, MD; Amy R. Marks, MPH; Wei K. Zhao, MPH; Nirupa R. Ghai, PhD; Alexander T. Lee, MD; Richard Contreras, MS; Charles P. Quesenberry, PhD; Bruce H. Fireman, MA; Theodore R. Levin, MD



Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis

Figure 1. Flow of Patients Through the Study



FIT indicates fecal immunochemical test; KPNC, Kaiser Permanente Northern California; KPSC, Kaiser Permanente Southern California.



Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis

Table 2. Colorectal Cancer Outcomes in Patients Who Received a Colonoscopy After a Positive FIT Result

	Time to Colonoscopy, No. of Patients (%) ^a								
Characteristics	8-30 Days	2 Months	3 Months	4-6 Months	7-9 Months	10-12 Months	>12 Months	Total	
Advanced adenoma ^b	2135 (8.1)	2168 (9.0)	779 (9.3)	429 (8.4)	114 (8.9)	75 (10.5)	247 (11.6)	5947 (8.8)	
Any colorectal cancer	807 (3.0)	685 (2.8)	265 (3.1)	165 (3.1)	58 (4.3)	37 (4.9)	174 (7.6)	2191 (3.1)	
Advanced-stage colorectal cancer ^c									
Present	219 (0.8)	173 (0.7)	60 (0.7)	46 (0.9)	17 (1.3)	14 (1.9)	72 (3.1)	601 (0.9)	
Unknown	3 (<1)	2 (<1)	2 (<1)	2 (<1)	0	1 (0.1)	4 (0.2)	14 (<1)	
Colorectal cancer stage									
0	129 (0.5)	113 (0.5)	39 (0.5)	32 (0.6)	7 (0.5)	6 (0.8)	17 (0.7)	343 (0.5)	
I	314 (1.2)	275 (1.1)	122 (1.4)	48 (0.9)	19 (1.4)	5 (0.7)	40 (1.7)	823 (1.2)	
II	142 (0.5)	122 (0.5)	42 (0.5)	37 (0.7)	15 (1.1)	11 (1.5)	41 (1.8)	410 (0.6)	
III	169 (0.6)	133 (0.5)	56 (0.6)	32 (0.6)	12 (0.9)	9 (1.2)	49 (2.1)	460 (0.7)	
IV	50 (0.2)	40 (0.2)	4 (<1)	14 (0.3)	5 (0.4)	5 (0.7)	23 (1.0)	141 (0.2)	
Unknown	3 (<1)	2 (<1)	2 (<1)	2 (<1)	0	1 (0.1)	4 (0.2)	14 (<1)	
No colorectal cancer	26 369 (97.0)	23 959 (97.2)	8401 (96.9)	5086 (96.9)	1277 (95.7)	711 (95.1)	2130 (92.4)	67 933 (96.9	



Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk

of Colorectal Cancer and Cancer Stage at Diagnosis

Figure 2. Time to Colonoscopy After a Positive FIT and Adjusted Risk^a of Advanced Adenoma, Any Colorectal Cancer, and Advanced-Stage Colorectal Cancer

2 mo 2 3 mo 4-6 mo 7-12 mo >12 mo	2135/26369 2168/23959 779/8401 429/5086 189/1988	81 (78-84) 91 (87-94) 93 (87-99) 84 (77-92)	1 [Reference] 1.09 (1.03-1.17) 1.08 (0.99-1.18)		φ		
2 mo 2 3 mo 4-6 mo 7-12 mo >12 mo	2168/23959 779/8401 429/5086	91 (87-94) 93 (87-99)	1.09 (1.03-1.17) 1.08 (0.99-1.18)				
3 mo 4-6 mo 7-12 mo >12 mo	779/8401 429/5086	93 (87-99)	1.08 (0.99-1.18)				
4-6 mo 7-12 mo >12 mo	429/5086				-		
7-12 mo >12 mo	•	84 (77-92)			-		
>12 mo	189/1988	(/	0.97 (0.86-1.08)	-	-		
		95 (82-108)	1.07 (0.92-1.26)	-	-		
	247/2130	116 (102-130)	1.32 (1.15-1.52)		-		
Any colorectal cancer							
8-30 d	807/27176	30 (28-32)	1 [Reference]		φ		
2 mo	685/24644	28 (26-30)	0.92 (0.83-1.02)	-	H		
3 mo	265/8666	31 (27-34)	0.95 (0.82-1.10)	-	<u> </u>		
4-6 mo	165/5251	31 (27-36)	0.98 (0.82-1.16)	-	<u> </u>		
7-12 mo	95/2083	46 (37-55)	1.37 (1.09-1.70)		-		
>12 mo	174/2304	76 (65-86)	2.25 (1.89-2.68)			_	
Advanced-stage colorectal	cancer						
8-30 d	219/27173	8 (7-9)	1 [Reference]				
2 mo	173/24642	7 (6-8)	0.85 (0.69-1.04)	_	+		
3 mo	60/8664	7 (5-9)	0.78 (0.58-1.04)	_	 		
4-6 mo	46/5249	9 (6-11)	0.98 (0.71-1.35)		<u> </u>		
7-12 mo	31/2082	15 (10-20)	1.55 (1.05-2.28)				
>12 mo	72/2300	31 (24-38)	3.22 (2.44-4.25)			_	_

Wait time to colonoscopy

- No increase in risk of overall CRC or advanced CRC with colonoscopy within 10 months
 - Higher risk of Stage II CRC at 7-9 months
 - Higher risk of any CRC, Stage II and IV, advanced stage CRC after 10 months



Questions

